Integra LifeSciences Holdings Corporation (IART) — Fair Value Analysis

Base-case fair value (P50): $18.48 · Current price: $17.73 · Verdict: Fairly Valued

The Verdict on IART

Based on our proprietary Monte Carlo simulations, INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is currently deemed Fairly Valued. The stock trades at $17.73, positioning it very close to our median fair value estimate (P50) of $18.48. This indicates that, on average across thousands of forward scenarios, IART's current market price is largely reflective of its intrinsic value. While an implied upside of +4.2% exists to our P50 target, it suggests a balanced risk/reward profile for the shares at this juncture, rather than a strong directional bias based purely on the median outcome.

How IART stacks up against peers

IART’s operational and financial health is categorized as average relative to its sector peers. This average quality tier aligns with our "Fairly Valued" verdict, suggesting that the company's fundamentals are robust enough to support its current market capitalization but do not warrant a significant premium or discount based on its intrinsic value drivers. The close proximity of $17.73 to our $18.48 estimate underscores this assessment, indicating that the market has largely priced in IART's current standing and future prospects as modeled by our simulations.

What this means for investors

For investors, IART's "Fairly Valued" status and average quality tier imply that significant alpha generation from a simple mispricing correction is less likely at $17.73. The modest +4.2% to our $18.48 suggests that while there is some headroom, it's not a compelling value proposition that screams undervaluation. Investors seeking deeper insights into IART should consider the full distribution of potential outcomes from our Monte Carlo simulations. Sign up for a free FairCurve account to see the complete bear and bull case distributions and track IART's fair value as new fundamentals are released.